Semaglutide for treating early alzheimer’s disease

Semaglutide is in clinical development for the treatment of early Alzheimer’s disease (AD). AD is the most common cause of dementia in the UK. AD is a progressive condition, which means the symptoms develop gradually over many years and eventually become more severe. It affects multiple brain functions. Dementia is the name for a group of symptoms associated with an ongoing decline of brain functioning. It can affect memory, thinking skills and other mental abilities. The exact cause of AD is not yet fully understood, although several factors are thought to increase your risk of developing the condition. These include increasing age and family history. There is currently no cure for AD, but medicines are available that can help relieve some of the symptoms.